Sunshine Biopharma Inc
SBFM1.470USD
+0.060+4.25%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
3.98MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Sunshine Biopharma Inc Unternehmen
Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
Unternehmensinformationen
BörsenkürzelSBFM
Name des UnternehmensSunshine Biopharma Inc
IPO-datumAug 15, 2008
CEODr. Steve N. Slilaty
Anzahl der mitarbeiter52
WertpapierartOrdinary Share
GeschäftsjahresendeAug 15
Addresse333 Las Olas Way
StadtFORT LAUDERDALE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33301
Telefon19543300684
Websitehttps://www.sunshinebiopharma.com/
BörsenkürzelSBFM
IPO-datumAug 15, 2008
CEODr. Steve N. Slilaty
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
1.85K
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew M. Keller
Dr. Andrew M. Keller
Independent Director
Independent Director
--
--
Mr. Marc Beaudoin
Mr. Marc Beaudoin
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Natan
Mr. David Natan
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Malek Chamoun
Mr. Malek Chamoun
Chief Development Officer
Chief Development Officer
1.85K
--
Dr. Steve N. Slilaty
Dr. Steve N. Slilaty
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
61.00
--
Mr. Camille Sebaaly
Mr. Camille Sebaaly
Chief Financial Officer, Secretary
Chief Financial Officer, Secretary
60.00
--
Dr. Abderrazzak Merzouki
Dr. Abderrazzak Merzouki
Chief Science Officer, Director
Chief Science Officer, Director
59.00
--
Mr. Michel Roy
Mr. Michel Roy
Chief Commercial Officer
Chief Commercial Officer
1.00
--
Dr. Rabi Kiderchah, M.D.
Dr. Rabi Kiderchah, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Wed, Jul 9
Aktualisiert: Wed, Jul 9
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
L1 Capital Global Opportunities Master Fund Ltd.
3.12%
Altium Capital Management LP
1.11%
UBS Financial Services, Inc.
0.44%
SBI Securities Co., Ltd.
0.11%
Morgan Stanley Smith Barney LLC
0.08%
Other
95.13%
Aktionäre
Aktionäre
Anteil
L1 Capital Global Opportunities Master Fund Ltd.
3.12%
Altium Capital Management LP
1.11%
UBS Financial Services, Inc.
0.44%
SBI Securities Co., Ltd.
0.11%
Morgan Stanley Smith Barney LLC
0.08%
Other
95.13%
Aktionärstypen
Aktionäre
Anteil
Corporation
3.12%
Investment Advisor/Hedge Fund
1.11%
Investment Advisor
0.52%
Research Firm
0.11%
Individual Investor
0.05%
Other
95.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
40
223.70K
4.91%
-115.64K
2025Q1
40
223.71K
4.97%
+181.45K
2024Q4
39
166.72K
8.34%
+112.42K
2024Q3
38
41.53K
13.09%
+24.77K
2024Q2
37
17.39K
14.86%
+11.35K
2024Q1
40
9.43K
19.69%
+5.56K
2023Q4
38
3.43K
26.72%
+270.00
2023Q3
34
2.71K
21.06%
-1.08K
2023Q2
34
3.32K
29.59%
+626.00
2023Q1
34
2.26K
20.01%
-741.00
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
L1 Capital Global Opportunities Master Fund Ltd.
142.24K
3.12%
+139.60K
+5281.91%
Dec 31, 2024
Altium Capital Management LP
50.47K
1.11%
+48.60K
+2607.40%
Mar 31, 2025
UBS Financial Services, Inc.
19.89K
0.44%
+19.02K
+2190.90%
Mar 31, 2025
SBI Securities Co., Ltd.
5.22K
0.11%
+4.51K
+636.67%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
3.83K
0.08%
--
--
Mar 31, 2025
Chamoun (Malek)
1.85K
0.04%
--
--
Apr 01, 2025
Slilaty (Steve N)
61.00
0%
--
--
Apr 01, 2025
Sebaaly (Camille)
60.00
0%
--
--
Apr 01, 2025
Merzouki (Abderrazzak)
59.00
0%
--
--
Apr 01, 2025
National Bank of Canada
10.00
0%
+3.00
+42.86%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Datum
Art
Verhältnis
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Aug 06, 2024
Merger
20<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
Apr 12, 2024
Merger
100<1
